Co-Founder Dr Kohkan Shamsi confirmed as RSNA 2022 speaker

Dr Kohkan Shamsi, RadMD co-founder, has been confirmed as a speaker for RSNA 2022 Dr Shamsi is booked to discuss “The Effect of Food Intake on Pharmacodynamics of A Novel Oral Liver-specific Contrast Agent: Orviglance (Manganese Chloride…

More

Clinical Evidence Supports Dotarem® Injection for MR Imaging

New Article in Applied Radiology, the Journal of Practical Medical Imaging and Management: Magnetic resonance imaging (MRI) contrast agents are widely used to increase the contrast difference between normal and abnormal tissues. Also known as…

More

RadMD managed imaging for a phase II trial for Ipsen biopharmaceuticals’ new Gallium PET imaging agent

RadMD managed imaging for a phase II trial for Ipsen biopharmaceuticals’ new Gallium PET imaging agent to assess somatostatin receptor (SSTR2) positive gastroenteropancreatic neuroendotrine tumor (GEP-NET) that employed novel independent read…

More

Kohkan Shamsi, in collaboration with ICPME, develops an accredited course

Kohkan Shamsi, in collaboration with ICPME, develops an accredited course intended to educate on the potential implications of ordering and performing contrast-enhanced MRIs The use of gadolinium-based contrast agents in MR imaging has been…

More

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease:

A randomised, controlled, double-blind, parallel-arm, phase 3 trial. Leuco-methylthioninium bis(hydromethanesulfonate; LMTM), a stable reduced form of the methylthioninium moiety, acts as a selective inhibitor of tau protein aggregation both in…

More

JAMA Article on Gadolinium Exposure and Parkinson’s: A False Sense of Safety?

Welk B, McArthur E, Marrow SA, et al. Association between Gadolinium contrast Exposure and the Risk of Parkinsonism Dr. Welk and colleagues conducted a retrospective review of multiple linked administrative databases from Ontario, Canada to evaluate…

More

Deposition of Gadolinium in After Multiple GBCA Injections: Clinical Trial Prospective

Gadolinium-based contrast agents (GBCAs) are indispensable adjuncts to MRI, with numerous studies showing their efficacy in improving the accuracy of MRI studies. Gadolinium deposition in the brains of patients who received multiple doses of GBCAs…

More

RadMD Principal publishes in Nature Medicine

RadMD Principal, Rick Patt, MD was recently published in Nature Medicine magazine. The article entitled “Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer” was published in March 2013.…

More

RadMD Announces 2013 Webinar Series

RadMD Experts will conduct a series of Educational Webinars throughout 2013. The first in the series, “Current Issues and Role of Imaging in Alzheimer’s Disease Trials” will be hosted by Dr. Kohkan Shamsi, Principal at RadMD, on…

More